(Q50861558)

English

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

3

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

author name string

Andy K Hsu

2

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Anas Younes

4

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Anna Sureda

5

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Andreas Engert

6

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

H Miles Prince

7

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Martha Li

8

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Paula Savage

9

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Roberto Bugarini

10

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Denise Williams

11

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Margaret Squier

12

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

David S Ritchie

13

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

publication date

5 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

55

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

5

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

1053-1060

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

The role of chemokines in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

STAT3 is constitutively activated in Hodgkin cell lines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Optimising the lymphoma response criteria in the era of targeted therapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

THE ORIGIN OF HODGKIN AND REED/STERNBERG CELLS IN HODGKIN'S DISEASE

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

A methodological framework to enhance the clinical success of cancer immunotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.820287

21 January 2018

Identifiers

10.3109/10428194.2013.820287

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

release_m2nz7l37ifenfcwhelzufpk4gu

1 reference

https://api.fatcat.wiki/v0/release/m2nz7l37ifenfcwhelzufpk4gu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23822537

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50861558&oldid=1843569669"